Iovance biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

San carlos, calif., dec. 17, 2021 (globe newswire) -- iovance biotherapeutics, inc. (nasdaq: iova), a late-stage biotechnology company developing novel t cell-based cancer immunotherapies, today announced that on december 16, 2021 (the “date of grant”), the company approved the grant of inducement stock options covering an aggregate of 107,900 shares of iovance's common stock to eleven new non-executive employees.
IOVA Ratings Summary
IOVA Quant Ranking